Our Technology: AIM™ ACT Adoptive Cellular Therapy
NexImmune’s AIM™ platform is the foundation for our unique approach to immunotherapy. Our AIM nanoparticle technology enables the development of immunotherapies that orchestrate specific T cell function and trigger a precise immune response against disease.
An AIM™ Adoptive Cellular Therapy (ACT) product is manufactured using an AIM™ nanoparticle cocktail that contains multiple tumor-specific antigens and the AIM™ Enrichment and Expansion system. Combined, this propriety approach delivers populations of high quality CD8+ antigen-specific T cells within 14 days — optimized for deep and durable response potential.